Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2007041481) RAPID ACTING AND PROLONGED ACTING INSULIN PREPARATIONS
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

We claim:
1. A formulation comprising insulin selected from the group consisting of intermediate acting, and long acting insulin with an effective amount of a chelator and an acidifying agent to enhance the rate or amount of uptake by a patient.
2. The formulation of claim 1 further comprising a rapid acting insulin.

3. The formulation of claim 1, wherein the chelator is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), dimercaprol (BAL), penicillamine, alginic acid, Chlorella, Cilantro, Alpha Lipoic Acid, Dimercaptosuccinic Acid (DMSA), dimercaptopropane sulfonate (DMPS), and oxalic acid.
4. The formulation of claim 3, wherein the chelator is
ethylenediaminetetraacetic acid (EDTA).
5. The formulation of claim 1, wherein the agent is a charged compound and wherein the chelator and solubilizing agent are present in effective amounts to mask charges on the agent.
6. The formulation of claim 1 wherein the solubilizing agent is an acid selected from the group consisting of acetic acid, ascorbic acid, citric acid, and hydrochloric acid.
7. The formulation of claim 6 wherein the solubilizing agent is citric acid.
8. The formulation of claim 1, wherein the insulin is natural or recombinant human insulin.
9. The formulation of claim 1 or 2 in a solid formulation for
administration to a mucosal surface.
10. The formulation of claim 1 or 2 in a formulation for administration by injection.
11. A formulation suitable for pulmonary administration of an insulin in combination with an effective amount of a chelator and an acidifying agent to enhance the rate or amount of uptake by a patient.

12. The formulation of claim 11 wherein the insulin is a natural or recombinant insulin selected from the group consisting of rapid, intermediate and long acting insulins.
13. A method of administering insulin to a patient in need thereof comprising administering the formulation of any of claims 1-12 to the patient.
14. The method of claim 13 wherein the formulation is administered to a mucosal surface selected from the group consisting of oral, sublingual, buccal, nasal, rectal, or vaginal.
15. The method of claim 13 comprising administering the formulation of claim 10 or 11 to the pulmonary region of a patient.
16. The method of claim 13 wherein the formulation of any of claims 1-10 is administered by injection.